
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
1,764.00 | 1,764.50 | 1,789.00 | 1,761.50 | 1,786.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | USD 2.52B | USD 188M | USD 0.8507 | 20.74 | 3.9B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
18:48:47 | O | 137 | 1,751.46 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
01/12/2023 | 07:00 | UKREG | Hikma Pharmaceuticals Plc Total Voting Rights |
02/11/2023 | 08:53 | ALNC | ![]() |
02/11/2023 | 07:00 | UKREG | Hikma Pharmaceuticals Plc Trading Statement |
02/10/2023 | 09:13 | UKREG | Hikma Pharmaceuticals Plc Block listing Interim Review |
02/10/2023 | 09:04 | UKREG | Hikma Pharmaceuticals Plc Total Voting Rights |
01/9/2023 | 06:00 | UKREG | Hikma Pharmaceuticals Plc Total Voting Rights |
31/8/2023 | 18:06 | UKREG | Hikma Pharmaceuticals Plc Director/PDMR Shareholding |
30/8/2023 | 16:55 | ALNC | ![]() |
23/8/2023 | 13:07 | ALNC | ![]() |
22/8/2023 | 16:26 | ALNC | ![]() |
Hikma Pharmaceuticals (HIK) Share Charts1 Year Hikma Pharmaceuticals Chart |
|
1 Month Hikma Pharmaceuticals Chart |
Intraday Hikma Pharmaceuticals Chart |
Date | Time | Title | Posts |
---|---|---|---|
03/11/2023 | 00:11 | Hikma Pharmaceuticals | 1,754 |
13/1/2015 | 15:12 | *** Hikma *** | 98 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 10/12/2023 08:20 by Hikma Pharmaceuticals Daily Update Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,783p.Hikma Pharmaceuticals currently has 220,988,500 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £3,899,342,083. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 20.74. This morning HIK shares opened at 1,786p |
Posted at 30/8/2023 07:57 by robertball Not caught by Us drug announcement yesterday re price controls... |
Posted at 28/4/2023 08:13 by robertball I'm here. This share is overlooked. Sigi's resignation was a bit of a blow and appointing an internal candidate was a vote of no confidence.It's a family firm and it might do OK in the long term.Not for speculators |
Posted at 02/3/2023 19:01 by ariane Iain GilbertSharecast News 27 Feb, 2023 16:26 27 Feb, 2023 16:27 Broker tips: Hikma Pharmaceuticals Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update. Berenberg stated that last week, Hikma reported "decent" 2022 results, in its view, with no real changes to the group's outlook from January when management presented at a competitor conference. |
Posted at 02/3/2023 17:43 by waldron RBC raises Hikma Pharma price target to 1,950 (1,750) pence - 'outperform' |
Posted at 08/2/2023 13:45 by adamb1978 Share price has had a nice run over the last 3-4 months however is still very cheap if you believe it can grow at mid single digit %s which market forecasts suggest and generate the 20%-ish ROCE which it historically has.If you believe in mean reversion and see it getting back to multiples over the last few years, this should be heading to £25-£30 |
Posted at 30/9/2022 09:32 by cumnor Bought in here at £13 avg. Now the diversity nonsense is out of the way these guys (and gals I suppose) need to up the ante on their dividend payments if they wish to recover the share price..... |
Posted at 15/9/2022 11:01 by swinsco Jeffries have just cut Hik price target to 2020 from 2200 and keep it a buy rating. Broker nonsense! |
Posted at 01/9/2022 10:56 by mjneish Good to see HIK outperforming the wider market at the moment. FTSE down 1.5% at the moment, and HIK down only 1%. :) |
Posted at 18/8/2022 19:32 by cumnor Punters and IIs are tiring of indebted companies like Hikma which paid divis of 2% for past couple of years, promised the earth and fail to deliver, as recent results show. Meanwhile directors pay themselves huge salaries and bonuses but expect investors to pay dear for the measly dividend. This could have been more generous and the recent falls (not just here) in poor payers share prices reflect a change in attitude to greedy directors.Needs to see a divi of 5% plus before I'd touch this. |
Posted at 04/8/2022 09:06 by adamb1978 Even taking historic earnings, PE is only around 11x. It feels like there's a lot of negativity built into the share price here. To justify this sort of multiple, you need to believe that the business is going to be more of less flat going forwardsNo investment is a sure thing, and they're all an assessment of upside and downside potential. It feels to me that the multiple provides for a lot of downside protection here, and probably far too much |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |